Epizyme, Inc. (NASDAQ:EPZM) has been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $22.67.
A number of analysts recently weighed in on EPZM shares. BidaskClub raised shares of Epizyme from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the company a “buy” rating in a research report on Saturday, August 5th. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Leerink Swann reissued an “outperform” rating and set a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research report on Wednesday, August 9th. Finally, Cann restated a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Tuesday, September 19th.
Epizyme (EPZM) opened at $12.00 on Friday. Epizyme has a 52 week low of $9.30 and a 52 week high of $20.45.
In other Epizyme news, Director David M. Mott acquired 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were purchased at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock in a transaction on Monday, September 25th. The shares were sold at an average price of $16.81, for a total value of $252,150.00. Following the sale, the insider now directly owns 23,123 shares of the company’s stock, valued at approximately $388,697.63. The disclosure for this sale can be found here. 25.20% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in EPZM. Legal & General Group Plc increased its stake in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 795 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Epizyme by 3.3% during the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after acquiring an additional 1,068 shares in the last quarter. Rhumbline Advisers increased its position in shares of Epizyme by 2.6% during the second quarter. Rhumbline Advisers now owns 50,140 shares of the biopharmaceutical company’s stock worth $757,000 after acquiring an additional 1,257 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Epizyme by 1.5% during the second quarter. Principal Financial Group Inc. now owns 95,572 shares of the biopharmaceutical company’s stock worth $1,443,000 after acquiring an additional 1,399 shares in the last quarter. Finally, Teachers Advisors LLC increased its position in shares of Epizyme by 3.1% during the first quarter. Teachers Advisors LLC now owns 69,922 shares of the biopharmaceutical company’s stock worth $1,199,000 after acquiring an additional 2,093 shares in the last quarter. 85.28% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/01/epizyme-inc-epzm-receives-average-recommendation-of-buy-from-brokerages.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.